Black Diamond Therapeutics (BDTX) Stock Price, News & Analysis

Company Overview

Black Diamond Therapeutics, Inc. is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments.

The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations. Black Diamond’s approach seeks to overcome resistance mechanisms that often limit the efficacy of existing therapies by focusing on mutation-specific vulnerabilities. Early-stage clinical trials for BDTX-189 are evaluating safety, pharmacokinetics, and anti-tumor activity in patients whose tumors harbor HER2 alterations.

Founded in 2019 and listed on the Nasdaq under the ticker BDTX, Black Diamond Therapeutics combines scientific expertise with experience drawn from leading biopharmaceutical organizations. The company collaborates with academic centers and research institutions to advance its pipeline and is committed to delivering next-generation precision medicines to oncology patients worldwide.

Key Stats

• Today's Range: $2.43 to $2.79
• 50-Day Range: $2.03 to $3.35
• 52-Week Range: $1.53 to $4.94
• Volume: 1.93 million shs
• Average Volume: 863,633 shs
• Market Capitalization: $155.86 million
• P/E Ratio: 7.35
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Moderate Buy

Black Diamond Therapeutics Stock Analysis - MarketRank™

Black Diamond Therapeutics scored higher than 73% of companies evaluated by MarketBeat, and ranked 177th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Black Diamond Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 1 strong buy rating, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Black Diamond Therapeutics has a consensus price target of $10.00, representing about 267.6% upside from its current price of $2.72.

Amount of Analyst Coverage

Black Diamond Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Black Diamond Therapeutics are expected to decrease in the coming year, from ($0.60) to ($0.93) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Black Diamond Therapeutics is 7.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 44.14.

Price to Earnings Ratio vs. Sector

The P/E ratio of Black Diamond Therapeutics is 7.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.45.

Price to Book Value per Share Ratio

Black Diamond Therapeutics has a P/B Ratio of 1.38. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.16% of the float of Black Diamond Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Black Diamond Therapeutics has a short interest ratio ("days to cover") of 6.68.

Change versus previous month

Short interest in Black Diamond Therapeutics has recently increased by 8.01%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Black Diamond Therapeutics does not currently pay a dividend.

Dividend Growth

Black Diamond Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 4.5 / 5
• News Sentiment: 1.23

News Sentiment

Black Diamond Therapeutics has a news sentiment score of 1.23. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Black Diamond Therapeutics this week, compared to 2 articles on an average week.

Search Interest

19 people have searched for BDTX on MarketBeat in the last 30 days. This is an increase of 850% compared to the previous 30 days.

MarketBeat Follows

6 people have added Black Diamond Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Black Diamond Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

5.97% of the stock of Black Diamond Therapeutics is held by insiders.

Percentage Held by Institutions

95.47% of the stock of Black Diamond Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

BDTX Stock Analysis - Frequently Asked Questions

How have BDTX shares performed this year?

Black Diamond Therapeutics' stock was trading at $2.43 at the beginning of the year. Since then, BDTX stock has increased by 11.9% and is now trading at $2.72.

How were Black Diamond Therapeutics' earnings last quarter?

Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) posted its earnings results on Monday, May, 11th. The company reported ($0.16) EPS for the quarter, topping analysts' consensus estimates of ($0.18) by $0.02.

When did Black Diamond Therapeutics IPO?

Black Diamond Therapeutics (BDTX) raised $180 million in an initial public offering (IPO) on Thursday, January 30th 2020. The company issued 10,586,316 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Black Diamond Therapeutics' major shareholders?

Black Diamond Therapeutics' top institutional shareholders include Dimensional Fund Advisors LP (2.27%), Bank of New York Mellon Corp (0.33%), Ritholtz Wealth Management (0.29%) and Brookstone Capital Management (0.02%). Insiders that own company stock include Ali Behbahani, Growth N V Biotech and David M Epstein.
View institutional ownership trends.

How do I buy shares of Black Diamond Therapeutics?

Shares of BDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Black Diamond Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Black Diamond Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), Ginkgo Bioworks (DNA), Compass Pathways (CMPS), Toast (TOST), Meta Platforms (META) and Luminar Technologies (LAZR).

Company Calendar

• Today: 5/08/2026
• Last Earnings: 5/11/2026
• Next Earnings (Estimated): 5/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BDTX
• CIK: 1701541
• Web: N/A
• Phone: 617-252-0848
• Fax: N/A
• Employees: 90
• Year Founded: 2017

Price Target and Rating

• Average Price Target for Black Diamond Therapeutics: $10.00
• High Price Target: $14.00
• Low Price Target: $8.00
• Potential Upside/Downside: +267.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.70
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.37
• Trailing P/E Ratio: 7.35
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $22.37 million
• Net Margins: N/A
• Pretax Margin: 31.95%
• Return on Equity: 23.19%
• Return on Assets: 18.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.42
• Quick Ratio: 8.42

Sales & Book Value

• Annual Sales: $70 million
• Price / Sales: 2.23
• Cash Flow: $0.51 per share
• Price / Cash Flow: 5.35
• Book Value: $1.97 per share
• Price / Book: 1.38

Miscellaneous

• Outstanding Shares: 57,300,000
• Free Float: 53,881,000
• Market Cap: $155.86 million
• Optionable: Optionable
• Beta: 3.34